lou gehrig

Two years ago researchers at the University of Pennsylvania School of Medicine discovered that misfolded proteins called TDP-43 accumulated in the motor areas of the brains of patients with Lou Gehrig's disease.

Now, the same group has shown that TDP-43 accumulates throughout the brain, suggesting the disease has broader neurological effects than previously appreciated and treatments need to take into account more than motor neuron areas.

Researchers are developing a novel approach to screen for drugs to combat neurodegenerative diseases such as amyotrophic lateral sclerosis, or Lou Gehrig's disease -- using yeast cells.

The clumping process of proteins takes decades in humans but the researchers could model the process within a matter of hours in yeast cells.

This now allows for rapid genetic screening to identify proteins that can reverse the harmful effects of the disease protein; visualizing the clumping; and testing molecules that could eliminate or prevent clumping.

Preliminary but encouraging findings from a Phase 0 human clinical trial of a melanoma drug have been reported. Scientists found an approved drug used to treat Lou Gehrig's disease (ALS), slows the growth of melanoma, the most aggressive form of malignant skin cancer.

Preliminary results show that a common environmental chemical may increase the risk of developing amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, according to new research.

Leaky blood vessels that lose their ability to protect the spinal cord from toxins may play a role in the development of amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig's disease, according to research in Nature Neuroscience.

In recent months a spate of mutations have been found in a disease protein called TDP-43 that is implicated in two neurodegenerative disorders: amyotrophic lateral sclerosis, also called Lou Gehrig's disease, and certain types of frontotemporal dementia.

These mutations could potentially become candidates for drug targets. Recently, scientists have found two more mutations.

Scientists have identified a novel gene responsible for a significant fraction of ALS (sporadic amyotrophic lateral sclerosis) cases.

ALS is commonly referred to as Lou Gehrig's disease, an incurable neuromuscular disorder that affects motor neurons and leads to paralysis and death within one to five years.

Scientists have identified a novel gene responsible for a significant fraction of ALS (sporadic amyotrophic lateral sclerosis) cases.

ALS is commonly referred to as Lou Gehrig's disease, an incurable neuromuscular disorder that affects motor neurons and leads to paralysis and death within one to five years.